Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Erythromycin (DBL)

Erythromycin (DBL) is a medicine containing the active ingredient(s) erythromycin lactobionate, erythromycin. On this page you will find out more about Erythromycin (DBL), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.

Active ingredient in this medicine: erythromycin lactobionate

Active ingredient in this medicine: erythromycin

Information for medicine and pack size:
Erythromycin (DBL) 250 mg enteric capsule, 25

Consumer Medicine Information leaflet:

This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.

Read leaflet

What this medicine is for

MAYNE PHARMA ERYTHROMYCIN is indicated in children and adults for the treatment of the following conditions: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes (group A beta haemolytic streptococci), Streptococcus pneumoniae (Diplococcus pneumoniae). Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes (group A beta hemolytic streptococci), Streptococcus pneumoniae (Diplococcus pneumoniae), acute and chronic bronchitis, pneumonia. Sinusitis caused by Streptococcus pneumoniae, Streptococcus pyogenes. Otitis media due to Streptococcus pneumoniae, Streptococcus pyogenes. Respiratory tract infections due to Mycoplasma pneumonia (Eaton's agent). Skin, and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes and Staphylococcus aureus (resistant staphylococci may emerge during treatment). Bordetella pertussis: Erythromycin produces early elimination of the causative organism from the nasopharynx although the clinical course of the disease is not altered; therapeutic doses should be continued for at least 10 days. Diphtheria: As an adjunct to antitoxin infections due to Corynebacterium diphtheriae, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Non-gonococcal Urethritis: Chlamydia trachomatis and Ureaplasma urealyticum have been shown to be sensitive to erythromycin and clinical studies have demonstrated its efficacy in urethritis due to these organisms. A minimum of 10 days therapy appears to be required. Chlamydia trachomatis infection (excluding Non-gonococcal urethritis): Erythromycin has been shown to be effective in the treatment of trachoma or inclusion-body conjunctivitis and pneumonia in infants caused by Chlamydia trachomatis. Campylobacter fetus (subspecies) jejuni: Infections due to this organism when antibiotic therapy is indicated. Primary syphilis caused by Treponema pallidum: Erythromycin (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins. In the treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the followup after therapy. Legionnaires' disease caused by Legionella pneumophila: Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prevention of initial attacks of rheumatic fever: Penicillin is considered by the American Heart Association (AHA) to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of group A beta - haemolytic streptococcal infections of the upper respiratory tract e.g. tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin allergic patients. A therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever: Penicillin or sulphonamides are considered by the AHA to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulphonamides, oral erythromycin is recommended by the AHA in the long term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). Prevention of bacterial endocarditis: Although no controlled clinical efficacy trials have been conducted, oral erythromycin has been suggested by the AHA and the American Dental Association in a regimen for prophylaxis against bacterial endocarditis in patients sensitive to penicillin who have congenital heart disease, or rheumatic or other acquired valvular heart disease when they undergo dental or surgical procedures of the upper respiratory tract. Erythromycin is not suitable prior to genitourinary or gastrointestinal tract surgery.

Table of characteristics
Table of characteristics
Active ingredient
Visual appearance A red/yellow gelatin capsule printed eryc in black, filled with white spheroidal pellets.

Images are the copyright of the Pharmacy Guild of Australia

Dosage Form Capsule, enteric
Route of administration Oral
Medicine schedule
25: Prescription Only Medicine, or Prescription Animal Remedy

There is one type of pack available.

Pack type 1
Pack type 1
Type Blister Pack
Storage temperature Store below 25 degrees Celsius
Storage conditions No information available
Life time 18 Months
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information

The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.

Go to PBS site

Is this medication banned in sport?

Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.

Go to ASADA site

The information displayed on this page is authored by Healthdirect Australia, or obtained from trusted sources.

Need more information?

These trusted information partners have more on this topic.

Found 7 results

Erythromycin Lactobionate for Intravenous Infusion (DBL) | myVMC

Erythromycin is an antibiotic used to treat mild-moderate bacterial infections including otitis media, bronchitis and pneumonia.

Read more on myVMC – Virtual Medical Centre website

DBL Erythromycin | myVMC

Erythromycin is an antibiotic used to treat sexually transmitted infections, respiratory tract infections and skin and soft tissues infections.

Read more on myVMC – Virtual Medical Centre website

DBL Docetaxel Concentrated Injection - myDr.com.au

DBL Docetaxel Concentrated Injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

DBL Ergometrine Injection Solution for injection - myDr.com.au

DBL Ergometrine Injection Solution for injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

DBL Azithromycin for Injection Powder for infusion - myDr.com.au

DBL Azithromycin for Injection Powder for infusion - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

DBL Phenytoin Injection BP Solution for injection - myDr.com.au

DBL Phenytoin Injection BP Solution for injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

DBL Ciprofloxacin Injection For Intravenous Infusion - myDr.com.au

DBL Ciprofloxacin Injection For Intravenous Infusion - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Healthdirect 24hr 7 days a week hotline

24 hour health advice and information you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo
Feedback